Current page location

Bioevaluation Center

Bio-evaluation Center
Objectives
Our aim is to establish a collective and specific infrastructure of techniques, facilities, and manpower to support the effective and successful development of biotech products. For this purpose, we have not only constructed developmental and evaluational infrastructure for optimizing, analyzing, and standardizing living modified organisms and drug candidates; but also assessed the usefulness and risks of biotech research and development processes and the biotech products themselves, to facilitate commercialization.
Researchers
researcher name and research fields
name research fields
Hyoung-Chin Kim
/ Associate Director
  • Experimental Animal Medicine
  • Toxicology
  • Health Safety of LMO
Jong Soon Kang
/ Principal Researcher
  • Molecular Pharmacology
  • Efficacy evaluation of drug candidates
Soon-Chun Jeong
/ Principal Researcher
  • Genetics of Plant Disease Resistance Genes / Molecular
  • Genetic Characterization of LMOs / Soybean Genomics
Stephen Beungtae Ryu
/ Principal Researcher(Concurrent Position)
  • Enhancement of multi-resistances of plants using natural lipids and plant green biotechnology on natural rubber
Chang-Gi Kim
/ Senior Researcher
  • Plant ecology / Environmental risk assessment of LMO
Soo Jin Oh
/ Senior Researcher
  • Drug metabolism and pharmacokinetics in drug discovery
Jung-Ho Park
/ Senior Researcher
  • Protein Engineering
Jieun Yun
/ Researcher
  • Cancer signaling
  • Efficacy evaluation of anti-cancer agents
In Soon Back
/ Technician
  • Molecular Genetic Characterization of LMOs
Chang Woo Lee
/ Principal Technician
  • In vivo efficacy evaluation
research areas
  • Living modified organisms (LMOs)
    • Conducting genetic analysis and assessing the risks of LMOs
  • New drugs
    • Discovery and preclinical evaluation of new drug candidates
Achievements
  • Living modified organisms
    • We have established and developed infrastructure for genetic analysis and risk assessments of living modified organisms. In particular, we have been assessing the potential risks of domestically developed transgenic rices, chilli peppers, potatoes, poplars and rootstocks for watermelons. We also conduct National Environmental Monitoring on domestic soybeans, corns and oilseed rapes and the inspect the extent of genetic contamination by imported LMOs.
  • Drug discovery
    • We developed and implemented an integrated infrastructure for drug discovery encompassing preclinical efficacy, ADME and toxicity evaluations. We have applied this technology platform to the discovery and preclinical evaluation of drug candidates in the areas of cancer and immune-related diseases and supported drug discovery in the pharmaceutical industry, academia and research institutes.
Selected Publications
  • Chang-Gi Kim (Co-Corresponding) Planta. 233(4):807-15.
    • Gene flow from herbicide-tolerant GM riceand the heterosis of GM rice-weed F2 progeny
  • Jong Soon Kang (First) Food Chem Toxicol. 49(9):2453-58.
    • Improvement of high-fat diet-induced obesity by a mixture of red grape extract, soy isoflavone and L-carnitine: Implications in cardiovascular and non-alcoholic fatty liver diseases
  • Soon-Chun Jeong (Corresponding) Theor Appl Genet. 122(5):865-74.
    • Fine genetic mapping of the genomic region controlling leaflet shape and number of seeds per pod in the soybean
  • Soon-Chun Jeong (Corresponding) Theor Appl Genet. 122(5):875-84.
    • Glycine max non-nodulation locus rj1: a recombinogenic region encompassing a SNP in a lysine motif receptor-like kinase (GmNFR1¥á)